DK3197868T3 - N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b - Google Patents

N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b Download PDF

Info

Publication number
DK3197868T3
DK3197868T3 DK15844057.8T DK15844057T DK3197868T3 DK 3197868 T3 DK3197868 T3 DK 3197868T3 DK 15844057 T DK15844057 T DK 15844057T DK 3197868 T3 DK3197868 T3 DK 3197868T3
Authority
DK
Denmark
Prior art keywords
oxyaryl
nr2b
octahydro
cyclopenta
pyrrol
Prior art date
Application number
DK15844057.8T
Other languages
Danish (da)
English (en)
Inventor
David R Anderson
Robert A Volkmann
Frank S Menniti
Original Assignee
Cadent Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55581945&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3197868(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadent Therapeutics Inc filed Critical Cadent Therapeutics Inc
Application granted granted Critical
Publication of DK3197868T3 publication Critical patent/DK3197868T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15844057.8T 2014-09-26 2015-09-23 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b DK3197868T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462056284P 2014-09-26 2014-09-26
PCT/US2015/051694 WO2016049165A1 (en) 2014-09-26 2015-09-23 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of nr2b

Publications (1)

Publication Number Publication Date
DK3197868T3 true DK3197868T3 (da) 2020-06-22

Family

ID=55581945

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15844057.8T DK3197868T3 (da) 2014-09-26 2015-09-23 N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b

Country Status (40)

Country Link
US (4) US10239835B2 (enExample)
EP (4) EP3683207B1 (enExample)
JP (5) JP6473227B2 (enExample)
KR (1) KR102479356B1 (enExample)
CN (1) CN106795111B (enExample)
AP (1) AP2017009832A0 (enExample)
AR (1) AR103199A1 (enExample)
AU (1) AU2015320721B2 (enExample)
BR (1) BR112017006093B1 (enExample)
CA (1) CA2962569C (enExample)
CL (1) CL2017000474A1 (enExample)
CO (1) CO2017002494A2 (enExample)
CR (1) CR20170114A (enExample)
CU (1) CU24482B1 (enExample)
CY (1) CY1123533T1 (enExample)
DK (1) DK3197868T3 (enExample)
EA (1) EA034937B1 (enExample)
EC (1) ECSP17025302A (enExample)
ES (3) ES2956546T3 (enExample)
GT (1) GT201700062A (enExample)
HR (1) HRP20200959T1 (enExample)
HU (1) HUE049698T2 (enExample)
IL (1) IL250909B (enExample)
JO (1) JO3579B1 (enExample)
LT (1) LT3197868T (enExample)
MX (1) MX374657B (enExample)
MY (1) MY182342A (enExample)
NZ (1) NZ729569A (enExample)
PE (1) PE20170893A1 (enExample)
PH (1) PH12017500513A1 (enExample)
PL (1) PL3197868T3 (enExample)
PT (1) PT3197868T (enExample)
RS (1) RS60497B1 (enExample)
SG (1) SG11201702023QA (enExample)
SI (1) SI3197868T1 (enExample)
TN (1) TN2017000076A1 (enExample)
TW (1) TWI687407B (enExample)
UY (1) UY36326A (enExample)
WO (1) WO2016049165A1 (enExample)
ZA (1) ZA201701061B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
CA3079617A1 (en) 2017-10-20 2019-04-25 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP2021503443A (ja) 2017-10-31 2021-02-12 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
EP3746421B1 (en) 2018-02-02 2023-11-29 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CR20200445A (es) 2018-03-05 2021-04-27 Arcus Biosciences Inc Inhibidores de la arginasa
CN113906033B (zh) 2019-06-04 2024-04-02 勃林格殷格翰国际有限公司 咪唑并吡嗪衍生物及其作为药剂的用途
WO2020245136A1 (en) * 2019-06-04 2020-12-10 Boehringer Ingelheim International Gmbh Purine derivatives, as nr2b negative modulators and the use thereof as medicament, in particular for treating depressive disorders
CN111481543A (zh) * 2020-05-21 2020-08-04 苏州健雄职业技术学院 Nr2b负变构调节剂联合gaba受体调节剂在制备治疗阿尔兹海默症的药物中的用途
CN116744922A (zh) * 2020-12-04 2023-09-12 诺华股份有限公司 Nr2b-nmda受体nam在治疗抑郁症中的剂量方案
KR20230116865A (ko) 2020-12-04 2023-08-04 노파르티스 아게 우울증의 치료를 위한 nr2b-nmda 수용체 nam의 투여요법
JP2021058765A (ja) * 2021-01-19 2021-04-15 株式会社藤商事 遊技機
WO2022204336A1 (en) * 2021-03-26 2022-09-29 Novartis Ag Novel cyclopental[c]pyrrol negative allosteric modulators of nr2b
EP4313042A4 (en) * 2021-03-26 2025-01-15 Novartis AG NEW CYCLOPENTA[C PYRROL NEGATIVE ALLOSTERIC MODULATORS OF NR2B
KR20250019704A (ko) 2022-06-02 2025-02-10 노파르티스 아게 우울증 장애의 치료에 사용하기 위한 온파스프로딜의 피하 투여 및 투약 방법
CN120981566A (zh) 2023-01-12 2025-11-18 诺华股份有限公司 工程化酮还原酶多肽
TW202539663A (zh) 2023-12-06 2025-10-16 瑞士商諾華公司 用於治療抑鬱障礙之組成物和方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532243A (en) 1992-02-14 1996-07-02 The Dupont Merck Pharmaceutical Company Antipsychotic nitrogen-containing bicyclic compounds
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
DE4341403A1 (de) 1993-12-04 1995-06-08 Basf Ag N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
US5726172A (en) * 1996-01-16 1998-03-10 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
CN1950082B (zh) 2004-03-03 2013-02-06 凯莫森特里克斯股份有限公司 双环和桥连的含氮杂环化物
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
PL1761542T3 (pl) * 2004-06-09 2008-06-30 Hoffmann La Roche Pochodne oktahydropirolo[3,4-c]pirolu i ich zastosowanie jako środków przeciwwirusowych
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ グループ リミテッド 抗細菌剤
HUP0401523A3 (en) 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
CA2603876A1 (en) 2005-04-19 2006-10-26 Merck & Co., Inc. N-alkyl-azacycloalkyl nmda/nr2b antagonists
EP2029536B1 (en) 2006-04-28 2013-08-28 Laboratorios Del. Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
EP1849772A1 (en) 2006-04-28 2007-10-31 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
TW200845977A (en) 2007-03-30 2008-12-01 Targacept Inc Sub-type selective azabicycloalkane derivatives
AU2008317057B8 (en) 2007-10-22 2014-02-13 Merck Sharp & Dohme Corp. Bicyclic Heterocycle Derivatives and their use as modulators of the activity of GPR119
US8304411B2 (en) 2008-01-23 2012-11-06 Jiangsu Hansoh Pharmaceutical Co., Ltd. Dicycloazaalkane derivates, preparation processes and medical uses thereof
EP2378885A4 (en) 2008-12-12 2013-01-02 Univ Vanderbilt 3.3.0 BICYCLIC GLYT1 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
FR2945534B1 (fr) * 2009-05-12 2012-11-16 Sanofi Aventis DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2945533B1 (fr) * 2009-05-12 2011-05-27 Sanofi Aventis Derives de cyclopenta°c!pyrrolyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
PL2521450T3 (pl) 2010-01-07 2015-07-31 Du Pont Grzybobójcze związki heterocykliczne
WO2011149993A2 (en) 2010-05-25 2011-12-01 Abbott Laboratories SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS
CN102432598A (zh) * 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 三环化合物、其制备方法及其在医药上的应用
FR2974729B1 (fr) 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
US8501768B2 (en) 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
JO3611B1 (ar) * 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
MX358679B (es) 2011-12-21 2018-08-31 Jiangsu Hengrui Medicine Co Derivado de anillo de heteroarilo de seis miembros de pirrol, método de preparación del mismo y usos médicos del mismo.
DK2900669T3 (da) 2012-09-25 2019-11-04 Hoffmann La Roche Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9418332B2 (en) 2013-08-16 2016-08-16 Qualcomm Incorporated Post ghost plasticity
ES2910848T3 (es) * 2013-09-26 2022-05-13 Cadent Therapeutics Inc Moduladores negativos de octahidro-ciclopenta[c]pirrol selectivos de NR2B
UA118582C2 (uk) 2014-03-26 2019-02-11 Ф. Хоффманн-Ля Рош Аг Біциклічні сполуки як інгібітори продукції аутотаксину (atx) і лізофосфатидилової кислоти (lpa)
JO3579B1 (ar) * 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول

Also Published As

Publication number Publication date
CA2962569C (en) 2023-09-19
US12145909B2 (en) 2024-11-19
EA034937B1 (ru) 2020-04-08
JP6473227B2 (ja) 2019-02-20
CY1123533T1 (el) 2022-03-24
KR102479356B1 (ko) 2022-12-19
TW201625528A (zh) 2016-07-16
TWI687407B (zh) 2020-03-11
JP2019077713A (ja) 2019-05-23
BR112017006093A2 (pt) 2017-12-19
WO2016049165A1 (en) 2016-03-31
HRP20200959T1 (hr) 2020-10-02
SG11201702023QA (en) 2017-04-27
AU2015320721B2 (en) 2020-01-30
EP3197868A1 (en) 2017-08-02
US20190152912A1 (en) 2019-05-23
CN106795111B (zh) 2020-04-07
MX374657B (es) 2025-03-06
CO2017002494A2 (es) 2017-08-31
ZA201701061B (en) 2019-07-31
JP2025060835A (ja) 2025-04-10
EP3974420B1 (en) 2023-08-16
UY36326A (es) 2016-04-29
AU2015320721A1 (en) 2017-03-30
PT3197868T (pt) 2020-05-21
EP4282412A3 (en) 2024-01-17
EP4282412A2 (en) 2023-11-29
ES2911004T3 (es) 2022-05-17
US20220274925A1 (en) 2022-09-01
JP2023052515A (ja) 2023-04-11
US10239835B2 (en) 2019-03-26
CU20170037A7 (es) 2017-08-08
KR20170063599A (ko) 2017-06-08
AR103199A1 (es) 2017-04-26
ECSP17025302A (es) 2018-11-30
EP3683207A1 (en) 2020-07-22
US20180111902A1 (en) 2018-04-26
TN2017000076A1 (en) 2018-07-04
JP7612722B2 (ja) 2025-01-14
RS60497B1 (sr) 2020-08-31
MY182342A (en) 2021-01-20
CR20170114A (es) 2017-08-21
US10781174B2 (en) 2020-09-22
ES2956546T3 (es) 2023-12-22
AP2017009832A0 (en) 2017-03-31
MX2017003940A (es) 2018-03-01
CA2962569A1 (en) 2016-03-31
BR112017006093B1 (pt) 2023-03-21
JP2017528502A (ja) 2017-09-28
SI3197868T1 (sl) 2020-10-30
NZ729569A (en) 2019-06-28
EA201790713A1 (ru) 2017-07-31
EP3197868A4 (en) 2018-04-25
CU24482B1 (es) 2020-03-04
JP7216060B2 (ja) 2023-01-31
LT3197868T (lt) 2020-09-10
GT201700062A (es) 2019-09-30
EP3683207B1 (en) 2021-12-29
CL2017000474A1 (es) 2017-08-18
HUE049698T2 (hu) 2020-10-28
IL250909A0 (en) 2017-04-30
JP6772307B2 (ja) 2020-10-21
PH12017500513A1 (en) 2017-08-07
US20200369610A1 (en) 2020-11-26
EP3974420A1 (en) 2022-03-30
CN106795111A (zh) 2017-05-31
EP3197868B1 (en) 2020-04-15
ES2791327T3 (es) 2020-11-03
JP2021006554A (ja) 2021-01-21
JO3579B1 (ar) 2020-07-05
PE20170893A1 (es) 2017-07-12
IL250909B (en) 2019-06-30
PL3197868T3 (pl) 2020-11-02

Similar Documents

Publication Publication Date Title
DK3197868T3 (da) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b
DK3331876T3 (da) Modulators of ror-gamma
IL259421B (en) ror - gamma modulators
EP3383386A4 (en) MODULATORS OF CHEMOKIN RECEPTORS
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
DK3116316T3 (da) Allosteriske modulatorer af hepatitis b-kerneprotein
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3851537T3 (da) Behandling af hyperbilirubinæmi
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3433234T3 (da) Allosteriske modulatorer af nicotinacetylcholinreceptorer
DK3154561T3 (da) Modulering af komplementaktivitet
DK3389692T3 (da) Modulatorer af komplement-aktivitet
DK3220891T3 (da) Sublingual formulering af riluzol
BR112017026561A2 (pt) moduladores alostéricos positivos do receptor muscarínico m2
HUE056613T2 (hu) Komplementaktivitás modulátorai
HUE046888T2 (hu) Amid-szubsztituált tiazolok mint ROR-gamma-t modulátorok
EP2968296A4 (en) GAMMASEKRETASEMODULATOREN
DK3418273T3 (da) Derivater af flavagliner
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3297619T3 (da) Terapeutiske anvendelser af L-4-chlorkynurenin
DK3173071T3 (da) Formularing af maropitant
DK3248964T3 (da) Thiazol-modulatorer af A3-adenosinreceptorer
DK3212800T3 (da) 21-hydroxylering af steroider
FR3024647B1 (fr) Transat de puericulture
DK3161136T3 (da) Fremgangsmåde til berigelse af mikrovesikler